1037197-18-4Relevant articles and documents
Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV
Namoto, Kenji,Sirockin, Finton,Ostermann, Nils,Gessier, Francois,Flohr, Stefanie,Sedrani, Richard,Gerhartz, Bernd,Trappe, J?rg,Hassiepen, Ulrich,Duttaroy, Alokesh,Ferreira, Suzie,Sutton, Jon M.,Clark, David E.,Fenton, Garry,Beswick, Mandy,Baeschlin, Daniel K.
, p. 731 - 736 (2014/02/14)
The successful launches of dipeptidyl peptidase IV (DPP IV) inhibitors as oral anti-diabetics warrant and spur the further quest for additional chemical entities in this promising class of therapeutics. Numerous pharmaceutical companies have pursued their proprietary candidates towards the clinic, resulting in a large body of published chemical structures associated with DPP IV. Herein, we report the discovery of a novel chemotype for DPP IV inhibition based on the C-(1-aryl-cyclohexyl)-methylamine scaffold and its optimization to compounds which selectively inhibit DPP IV at low-nM potency and exhibit an excellent oral pharmacokinetic profile in the rat. 2014 Elsevier Ltd. All rights reserved.
